Completed PHASE2 INTERVENTIONAL NCT00074620

A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis

A Randomised, Multicenter, Open-Label, Parallel Group Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Unfractionated Heparin as Anticoagulant Treatment in Patients Undergoing Haemodialysis Via an Arteriovenous Graft

Sponsor: Quintiles, Inc.

Conditions Chronic Kidney Failure Vascular Graft Occlusion

Interventions PEG-hirudin

Updated 5 times since 2017 Last updated: Oct 4, 2007 Started: Nov 30, 2003 Completion: Jan 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Chronic Kidney Failure and Vascular Graft Occlusion, this trial is completed. The trial is conducted by Quintiles, Inc. and has accumulated 5 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Quintiles, Inc.
Speedel Pharma Ltd.

Data source: Speedel Pharma Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Philadelphia, United States